Home care pharmacy: Extending clinical pharmacy services beyond infusion therapy

American Journal of Health-System Pharmacy

Volumn 57, Issue 14, 2000, Pages 1326-1331

  Triller, Darren M ^a   Hamilton, Robert A ^c   Briceland, Laurie L ^c   Waite, Nancy M ^c   Audette, Christine M ^c   Furman, Carol A ^b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b Neurologic Associates Albany   (United States)

^c NONE

Author keywords

Administration; Antibiotics; Cisapride; Clinical pharmacists; Clinical pharmacy; Drug information; Drug use; Gastrointestinal drugs; Geriatrics; Health care; Heart failure; Interventions; Long term care facilities; Patient care; Pharmaceutical care; Pharmaceutical services; Vancomycin

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CISAPRIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ADULT; AGED; ARTICLE; CLINICAL PHARMACY; CONGESTIVE HEART FAILURE; DRUG INFORMATION; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; EXFOLIATION SYNDROME; FEMALE; HOME CARE; HUMAN; INFUSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PHARMACEUTICAL CARE; PHARMACIST; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 0034661921     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/57.14.1326     Document Type: Article

References (33)

1. Leape LL, Cullen DJ, Clapp MD et al. Pharmacist participation on physical rounds and adverse drug events in the intensive care unit. JAMA. 1999; 282:267-70.
2. Lesar TS, Briceland L, Stein DS. Factors related to errors in medication prescribing. JAMA. 1997; 277:312-7.
3. 42 C.F.R. §483(B).
4. Triller DM, Briceland LL, Waite NM et al. Is there a pharmacist in the house? Opportunities for pharmacy intervention within a Visiting Nurse Association (VNA). Paper presented at International Congress on Clinical Pharmacy. Orlando, FL; 1999 Apr.
5. Triller DM, Hamilton RA, Briceland LL et al. Experiential program at Visiting Nurse Association (VNA). Paper presented at American Association of Colleges of Pharmacy annual meeting. Boston, MA; 1999 Jul.
6. American Society of Health-System Pharmacists. ASHP guidelines: minimum standard for home care pharmacies. Am J Health-Syst Pharm. 1999; 56:629-38.
7. Health Care Financing Administration. Medicare and Medicaid programs: comprehensive assessment and use of the OASIS as part of the conditions of participation for home health agencies, Fed Regist. 1999; 64: 3764-84.
8. Triller DM, Hamilton RA, Kennicutt J et al. Identification of risk factors for hospitalization of patients with CHF receiving home nursing care. Paper presented at International Congress on Clinical Pharmacy. Orlando, FL: 1999 Apr.
9. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987; 316:1429-35.
10. The SOLVD Investigators. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991; 325:293-302.
11. Packer M, Bristow MR, Cohn JN et al. Effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996; 334:1349-55.
12. Packer M, Colucci WS, Sackner-Bernstein JD et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective randomized evaluation of carvedilol on symptoms and exercise, Circulation. 1996; 94:2793-9.
13. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344:1383-9.
14. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333:1301-7.
15. Cairns JA, Theroux P, Lewis HD Jr et al. Antithrombotic agents in coronary artery disease. Chest. 1998; 114:611S-33S.
16. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999; 353:2001-7.
17. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999; 353:9-13.
18. Gattis WA, Hasselblad V, Whellan DJ et al. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. Arch Intern Med. 1999; 159:1939-45.
19. Rainville EC. Impact of pharmacist interventions on hospital readmissions for heart failure. Am J Health-Syst Pharm. 1999; 56: 1339-42.
20. American Society of Health-System Pharmacists. ASHP guidelines on a standardized method for pharmaceutical care. Am J Health-Syst Pharm. 1996; 53:1713-6.
21. Propulsid package insert. Titusville, NJ: Janssen Pharmaceutica; 1999 Oct.
22. Moellering RC Jr. Monitoring serum vancomycin levels: climbing the mountain because it is there? Clin Infect Dis. 1994; 18: 544-6. Editorial.
23. Freeman CD, Quintiliani R, Nightingale CH. Vancomycin therapeutic drug monitoring: is it necessary? Ann Pharmacother. 1993; 27:594-8.
24. Karam CM, McKinnon PS, Neuhauser MM et al. Outcome assessment of minimizing vancomycin monitoring and dosing. Pharmacotherapy. 1999; 19:257-66.
25. Andres I, Lopez R, Pou L et al. Vancomycin monitoring: one or two serum levels? Ther Drug Monit. 1997; 19:614-9.
26. Tam VH, Moore G, Triller DM et al. Vancomycin peak serum concentration monitoring: implications for homecare. J Intraven Nurs. 1999; 22:336-41.
27. New York State Laws of 1980. The New York State Long Term Home Health Care Program. Chap. 636.
28. Triller DM, Bruce S, Hamilton RA. Reference databases to enhance pharmacy education and communication skills. Paper presented at American Association of Colleges of Pharmacy annual meeting. Boston, MA; 1999 Jul.
29. Triller DM, Miller MT, Briceland LL et al. Observation of trovafloxacin-associated exfoliative dermatitis in a homecare patient. Ann Pharmacother. 1999; 33:1122.
30. American Heart Association home page. www.americanheart.org/statistics/ 07 other.html (accessed 1999 Oct 14).
31. American Society of Consultant Pharmacists home page, www.ascp.com/public/pr/ qi_nfs.html (accessed 1999 Oct 14).
32. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure. Am J Cardiol. 1999; 83(suppl 2A): 1A-38A.
33. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). J Am Coll Cardiol. 1995; 26:1376-98.